| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/01/2002 | WO2002058750A2 A suspension comprising fibrinogen, thrombin and alcohol and a method of coating a carrier with the same |
| 08/01/2002 | WO2002058749A2 Carrier with solid fibrinogen and solid thrombin |
| 08/01/2002 | WO2002058738A2 Use of rad51 inhibitors for p53 gene therapy |
| 08/01/2002 | WO2002058735A1 Method of preparing biological materials and preparation produced using same |
| 08/01/2002 | WO2002058732A2 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058731A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058728A2 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses |
| 08/01/2002 | WO2002058724A2 Use of lp82 to treat body weight disorders |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058722A1 Method for diagnosing and treating dentinogenesis imperfecta type ii by using dentin sialophosphoprotein (dspp) gene and its encoding product |
| 08/01/2002 | WO2002058721A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | WO2002058720A2 Angiogenically effective unit dose of fgf-2 and method of use |
| 08/01/2002 | WO2002058719A1 Methods and compositions using cap43 proteins and nucleic acids to diagnose and treat cancer and other disorders |
| 08/01/2002 | WO2002058718A2 Use of compositions containing pdgf-bb for promoting angiogenesis |
| 08/01/2002 | WO2002058717A2 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 08/01/2002 | WO2002058716A2 Treatment of inflammatory bowel disease using growth factors |
| 08/01/2002 | WO2002058715A1 Prevention of diabetes by administration of gnrh antagonists |
| 08/01/2002 | WO2002058714A2 Methods and agents modulating upa/upar activity |
| 08/01/2002 | WO2002058712A2 Probiotic compounds derived from lactobacillus casei strain ke01 |
| 08/01/2002 | WO2002058709A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/01/2002 | WO2002058687A2 Inhibition of erk to reduce or prevent tolerance to and dependence on opioid analgesics |
| 08/01/2002 | WO2002058674A2 Process for preparing particles |
| 08/01/2002 | WO2002058673A1 Method of preparing pharmaceutical or dietary compositions for conveying labile substances into the intestine |
| 08/01/2002 | WO2002058671A1 Burst free pharmaceutical microparticules |
| 08/01/2002 | WO2002058638A2 Serpin drugs for treatment of hiv infection and method of use thereof |
| 08/01/2002 | WO2002058637A2 Compositions and methods for diagnosis of neuropsychiatric disorders |
| 08/01/2002 | WO2002058627A2 A cystic fibrosis transmembrane-conductance regulator (cftr)-membrane translocation sequence fusion protein (cftr-mts) as a therapeutic agent |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002058624A2 In situ generation allicin for the treatment of cancer and infectious diseases |
| 08/01/2002 | WO2002058589A2 Agents and methods for promoting bone growth |
| 08/01/2002 | WO2002058546A2 Methods for screening for substances which inhibit fp prostanoid receptor |
| 08/01/2002 | WO2002058535A2 Use of combretastatin a4 and its prodrugs as an immune enhancing therapy |
| 08/01/2002 | WO2002058534A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 08/01/2002 | WO2002058450A2 Regulation of cell growth by muc1 |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002038646A3 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 08/01/2002 | WO2002036761A9 Compositions and methods for the diagnosis of cancer |
| 08/01/2002 | WO2002036740A9 Apoptosis-inducing ribozymes |
| 08/01/2002 | WO2002034878A3 Amyloid precursor protein and app-derived peptides inhibit tumor growth and metastasis |
| 08/01/2002 | WO2002030441A3 Treatment of cancers by aplidine in conjunction with a myoprotector |
| 08/01/2002 | WO2002022166A3 Tweak receptor agonists as anti-angiogenic agents |
| 08/01/2002 | WO2002020614A3 Endoglin-specific polypeptide, production and use thereof |
| 08/01/2002 | WO2002020596A3 Maurotoxin, pi1 and hstx1 derivatives |
| 08/01/2002 | WO2002020031A3 Use of erythropoietin and the derivatives of the same for treating schizophrenia and related psychoses |
| 08/01/2002 | WO2002019986A9 Inducing cellular immune responses to hepatitis b virus using peptide and nucleic acid compositions |
| 08/01/2002 | WO2002017963A3 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 08/01/2002 | WO2002016617A3 Myrosinase from brevicoryne brassicae |
| 08/01/2002 | WO2002016437A3 Rhabdovirus-based vectors to express high levels of functional human antibodies |
| 08/01/2002 | WO2002014403A3 Acid end group poly(d,l-lactide-co-glycolide) copolymers with high glycolide content |
| 08/01/2002 | WO2002014359A3 Human serpin zserp15 |
| 08/01/2002 | WO2002010336A3 Mutacin i biosynthesis genes and proteins |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002004509A3 Gene expression, genome alteration and reporter expression in myofibroblasts and myofibroblast-like cells |
| 08/01/2002 | WO2002002625A3 Novel fibroblast growth factors and nucleic acids encoding same |
| 08/01/2002 | WO2002000684A3 Method of obtaining peptides with tissue-specific activity and pharmaceutical compositions on their basis |
| 08/01/2002 | WO2001098453A3 Modified construct downstream of the initiation codon for recombinant protein overexpression |
| 08/01/2002 | WO2001098367A3 Neuroactive peptides for treatment of hypoxia and related conditions |
| 08/01/2002 | WO2001098352A3 Thrombomodulin analogs for pharmaceutical use |
| 08/01/2002 | WO2001096565A3 Binding agents: chimeric ligand/receptor proteins |
| 08/01/2002 | WO2001092551A3 Duplexed parvovirus vectors |
| 08/01/2002 | WO2001090318A3 Regulation of human polyamine oxidase-like enzyme |
| 08/01/2002 | WO2001089319A3 Tryptophan source from plants and uses therefor |
| 08/01/2002 | WO2001083736A3 Internal de novo initiation sites of the hcv ns5b polymerase and use thereof |
| 08/01/2002 | WO2001083554A3 Anti-inflammatory compounds and uses thereof |
| 08/01/2002 | WO2001083527A3 Glucagon antagonists |
| 08/01/2002 | WO2001082953A3 Methods for treatment of diseases associated with inflammation under non-ischemic conditions |
| 08/01/2002 | WO2001082914A3 Topical anesthetic/opioid formulations and uses thereof |
| 08/01/2002 | WO2001081325A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 08/01/2002 | WO2001080633A3 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema |
| 08/01/2002 | WO2001075114A3 Chlamydia transmembrane protein as antigen, corresponding dna fragments and uses thereof |
| 08/01/2002 | WO2001075113A3 Chlamydia myosin heavy chain homolog as antigen, corresponding dna fragments and uses thereof |
| 08/01/2002 | WO2001075110A3 Mucin-1 specific binding members and methods of use thereof |
| 08/01/2002 | WO2001074863A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 08/01/2002 | WO2001072836A3 G-protein coupled receptors |
| 08/01/2002 | WO2001072335A3 Methods for effecting neuroprotection using a potassium channel modulator |
| 08/01/2002 | WO2001070979A9 Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer |
| 08/01/2002 | WO2001070950A3 Antisense nucleic acid molecules targeted to type i collagenase (mmp-1) for inhibition of melanoma invasion |
| 08/01/2002 | WO2001068655A3 Caprolactam derivatives and uses thereof |
| 08/01/2002 | WO2001062912A3 Method of modulating glycosylation pathways |
| 08/01/2002 | WO2001026678A9 Short segments of dap-kinase |
| 08/01/2002 | WO2001026675A9 FcηRIA |
| 08/01/2002 | WO2001026673A9 Antibiotic-metal complex and methods |
| 08/01/2002 | WO2001026672A9 Induction of a strong immune response to a self-tumor associated antigen |
| 08/01/2002 | WO2001022970A9 Therapy with 2-5a and interferon |
| 08/01/2002 | WO2001002000A9 Method and composition for affecting reproductive systems |
| 08/01/2002 | WO2001000667A9 Anti-thrombin peptide from anopheles albimanus salivary gland |
| 08/01/2002 | WO2000077040A9 Human intracellular signaling molecules |
| 08/01/2002 | US20020104113 Nav2 channel gene-deficient non-human animals |
| 08/01/2002 | US20020104112 Ikaros regulatory elements and uses thereof |
| 08/01/2002 | US20020104110 Immunologically privileged cells and uses thereof |
| 08/01/2002 | US20020103456 Vessel enlargement by arteriogenic factor delivery |
| 08/01/2002 | US20020103384 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| 08/01/2002 | US20020103366 One pot deprotection of preferential nucleotide sequences; obtain nucleotide sequences, incubate with triethylamine at room temperature, incubate with anhydrous triethylamine hydrogen fluoride, heat, recover nucletide sequences |
| 08/01/2002 | US20020103360 Novel protein related to melanoma-inhibiting protein and uses thereof |
| 08/01/2002 | US20020103358 Nucleotide sequences coding preferential polypeptide for use in tumor therapy |
| 08/01/2002 | US20020103354 Splicing variant of human membrane-type matrix metalloproteinase-5 (MT-MMP5-L) |
| 08/01/2002 | US20020103353 Sequences characteristic of hypoxia-regulated gene transcription |
| 08/01/2002 | US20020103346 Reptile venom polypeptide for use in reduction of complement activity |